Furthermore, ERBB2 mutations have been detected across various cancer types, with the highest prevalence reported in bladder cancer (9%-18%), followed by uterine and cervical cancers (6%), CRC (5.8%), lung (4%), and breast cancer (4%).8–11. This evidence concerns the gene ERBB2 and breast carcinoma.